# Aβ- and tau-associated neuroinflammatory signatures in Alzheimer's disease.

- **DOI:** [10.1002/trc2.70275](https://doi.org/10.1002/trc2.70275)
- **Rating:** Limited (2.7 out of 5)
- **Verdict:** PET-staged CSF proteomics identifies distinct inflammatory signatures, but cross-sectional contrasts cannot establish the claimed temporal waves or treatment strategy.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1002%2Ftrc2.70275

## Key claims

1. we identified distinct neuroinflammatory signatures related to broad downregulation of innate and adaptive immune proteins during Aβ accumulation, and upregulation of adaptive immune pathways with tau spread
   - Support: Supported
   - Type: Primary finding
   - Basis: PET-staged cross-sectional contrasts support distinct associations but not within-person temporal progression
   - Location: Research in Context, Interpretation
2. During the Aβ phase, 34 proteins were downregulated and mapped to 157 biological processes.
   - Support: Tentative
   - Type: Secondary
   - Basis: small cross-sectional comparison with a lenient enrichment threshold and unreconciled pathway totals
   - Location: Abstract, Results
3. The tau phase showed upregulation of 23 proteins associated with 82 biological processes enriched in adaptive immune responses.
   - Support: Tentative
   - Type: Secondary
   - Basis: protein direction is reported, but pathway breadth depends on lenient enrichment and inconsistent process totals
   - Location: Abstract, Results
4. A set of 48 biological processes and three proteins including interleukin 4 receptor, cystosolic phospholipase A2, and secretoglobin family 3A member 2 showed opposite regulation patterns.
   - Support: Supported
   - Type: Secondary
   - Basis: directional differences are reported across separate cross-sectional contrasts rather than a directly tested reversal
   - Location: Abstract, Results

## Strengths

- **PET-anchored inflammatory proteomic staging** The study combines Aβ and tau PET with a 368-analyte CSF inflammatory panel, allowing molecular comparisons across explicitly defined pathology groups rather than clinical categories alone.
  - Dimension: contribution
  - Location: Abstract, Methods, Study Population and CSF Proteomics
- **Transparent imaging and group definitions** Aβ positivity, tau Braak-like staging, PET acquisition, and the four analysis groups are described with explicit thresholds and sample sizes.
  - Dimension: methodological rigour
  - Location: Methods, PET and MRI Acquisition and Processing; Statistical Analysis
- **Concrete candidates for follow-up** IL4R, PLA2G4A, and SCGB3A2 provide named candidates for replication, alongside directional immune-process hypotheses that can be tested longitudinally.
  - Dimension: application pathway
  - Location: Abstract Results; Results, “Unique and shared inflammatory processes”

## Limitations

- **Cross-sectional contrasts framed as waves** The Aβ and tau signatures arise from different between-group comparisons, not repeated observations of the same individuals. The Discussion nevertheless describes two temporal waves and a transition between them.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Analysis; Discussion, opening and limitations paragraphs
- **Pathway totals do not reconcile** The reported 157 Aβ-phase and 82 tau-phase processes conflict with unique-plus-shared totals of 150 and 88. This inconsistency directly affects the pathway-level narrative.
  - Dimension: methodological rigour
  - Location: Results, “Aβ- and tau-associated neuroinflammatory proteins” and “Unique and shared inflammatory processes”
- **Therapeutic conclusions exceed evidence** The paper proposes stage-specific immune targets and states that successful immunomodulation will require stage-specific strategies, despite acknowledging that longitudinal validation is critical.
  - Dimension: positioning
  - Location: Discussion, therapeutic interpretation, limitations, and final paragraph

## Reliability checks

Concerns (4 of 4 checks).

- **Results check:** Concern
  - During the Aβ phase, 34 proteins were downregulated and mapped to 157 biological processes: "In the Aβ phase, we observed downregulation of 34 inflammatory proteins and 157 GO processes in Aβ‐positive individuals, spanning Toll‐like receptor signaling, NFκB activation, and T‐cell differentiation." (Discussion, paragraph 2) vs "We found 102 biological processes uniquely enriched in the Aβ phase and 40 uniquely enriched in the tau phase (Figure 3; Table S2). Forty‐eight inflammation‐related biological processes were common to the Aβ and tau phases all of them being downregulated in the Aβ phase and upregulated in the tau phase (Figure 3; Table S2)." (Results, Unique and shared inflammatory processes between Aβ and tau phases of AD). The reported partition gives 102 unique Aβ-phase processes plus 48 shared processes, totaling 150 rather than 157. → Changes the size materially
  - The tau phase showed upregulation of 23 proteins associated with 82 biological processes enriched in adaptive immune responses: "In the tau phase, the presence of widespread tau pathology is marked by the rise of 23 proteins and upregulation of 82 biological processes." (Discussion, paragraph 3) vs "We found 102 biological processes uniquely enriched in the Aβ phase and 40 uniquely enriched in the tau phase (Figure 3; Table S2). Forty‐eight inflammation‐related biological processes were common to the Aβ and tau phases all of them being downregulated in the Aβ phase and upregulated in the tau phase (Figure 3; Table S2)." (Results, Unique and shared inflammatory processes between Aβ and tau phases of AD). The reported partition gives 40 unique tau-phase processes plus 48 shared processes, totaling 88 rather than 82. → Changes the size materially
- **Reporting and transparency:** Noted. Reporting issues concern the enrichment threshold and its confidence interpretation, handling of excluded protein measurements, and the SC3GBA2 protein-name typo; their correction does not establish a change in the protein-level results.
  - Conflict of interest: declared · Ethics approval: declared · Data availability: not stated · Code availability: not stated
- **Reference integrity:** Clean
  - 27 references in manuscript
  - 27 of 27 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
